ArticleStem cell research & therapy2013
The dual role of mesenchymal stem cells in tumor progression.
Article in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements.Journal of translational medicine · 2025Review
- Recent developments in immunotherapy for gastrointestinal tract cancers.Journal of hematology & oncology · 2024Review
- Paeoniflorin drives the immunomodulatory effects of mesenchymal stem cells by regulating Th1/Th2 cytokines in oral lichen planus.Scientific reports · 2022Article
- Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition.Science advances · 2021Article
- Observational
- The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges.Cellular oncology (Dordrecht, Netherlands) · 2019Review
- Bidirectional and Opposite Effects of Naïve Mesenchymal Stem Cells on Tumor Growth and Progression.Advanced pharmaceutical bulletin · 2019Review
- Spontaneous formation of tumorigenic hybrids between human omental adipose-derived stromal cells and endometrial cancer cells increased motility and heterogeneity of cancer cells.Cell cycle (Georgetown, Tex.) · 2019Article
- Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways.Cancer cell international · 2019Review
- Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development.Stem cells translational medicine · 2017Review
- Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness.BMC cancer · 2015Article
- Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.Stem cell research & therapy · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) have attracted increasing interest in the field of oncology because of their inherent capacity to migrate and home tumor tissues. The remarkable tropism of MSCs for tumor microenvironments has been exploited in order to use these cells as cellular vehicles to deliver gene therapies or anticancer agents. At functional levels, these cells display chemotactic properties similar to those of immune cells in response to tissue insult and inflammation and secrete a broad range of bioactive biomolecules with an impact on tumor development and a progression through direct actions on tumor cells and the stromal microenvironment. However, the exact contribution of such interactions in tumor progression has not yet been fully clarified, and some concerns remain regarding whether MSCs exert a tumor-suppressive effect or, on the contrary, favor tumor growth. The article by Keramidas and colleagues in this issue of Stem Cell Research & Therapy provides an interesting contribution to this hot topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.